Compare NCSM & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | MIST |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 176.3M |
| IPO Year | 2017 | 2019 |
| Metric | NCSM | MIST |
|---|---|---|
| Price | $61.62 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 29.1K | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 239.22 | N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $142,471,000.00 | N/A |
| Revenue This Year | $5.57 | $1,653.36 |
| Revenue Next Year | $4.81 | $12.32 |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.20 | $0.63 |
| 52 Week High | $75.57 | $3.06 |
| Indicator | NCSM | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 46.10 |
| Support Level | $33.92 | N/A |
| Resistance Level | $75.57 | $2.01 |
| Average True Range (ATR) | 6.24 | 0.13 |
| MACD | -1.86 | -0.01 |
| Stochastic Oscillator | 13.91 | 48.10 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).